Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions

Reuters

08/15

<a href="https://laohu8.com/S/OVID">Ovid Therapeutics Inc.</a> Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions

Ovid Therapeutics Inc. recently released a corporate presentation highlighting its focus on developing medicines for conditions caused by neural hyperexcitability. The company is advancing a pipeline of highly specific small molecules with differentiated mechanisms of action. Key programs include the GABA-aminotransferase inhibitor OV329 for drug-resistant adult epilepsies and developmental epileptic encephalopathies, with Phase 1 topline results expected in Q3 2025 and Phase 2a initiation in Q1 2026. The KCC2 direct activator portfolio features OV350 IV, currently in Phase 1, and OV4071 oral, aimed at psychosis associated with Parkinson's disease and Lewy body dementia, with upcoming Phase 1 trials. Ovid holds a cash balance of $38.3 million, projected to fund operations into the early second half of 2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559896147"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559896147\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559896147?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559896147","market":"us","top_or_hot":-1,"title":"Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. recently released a corporate presentation highlighting its focus on developing medicines for conditions caused by neural hyperexcitability. The company is advancing a pipeline of highly specific small molecules with differentiated mechanisms of action. Key programs include the GABA-aminotransferase inhibitor OV329 for drug-resistant adult epilepsies and developmental epileptic encephalopathies, with Phase 1 topline results expected in Q3 2025 and Phase 2a initiation in Q1 2026. The KCC2 direct activator portfolio features OV350 IV, currently in Phase 1, and OV4071 oral, aimed at psychosis associated with Parkinson's disease and Lewy body dementia, with upcoming Phase 1 trials. Ovid holds a cash balance of $38.3 million, projected to fund operations into the early second half of 2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOvid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-15 04:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. recently released a corporate presentation highlighting its focus on developing medicines for conditions caused by neural hyperexcitability. The company is advancing a pipeline of highly specific small molecules with differentiated mechanisms of action. Key programs include the GABA-aminotransferase inhibitor OV329 for drug-resistant adult epilepsies and developmental epileptic encephalopathies, with Phase 1 topline results expected in Q3 2025 and Phase 2a initiation in Q1 2026. The KCC2 direct activator portfolio features OV350 IV, currently in Phase 1, and OV4071 oral, aimed at psychosis associated with Parkinson's disease and Lewy body dementia, with upcoming Phase 1 trials. Ovid holds a cash balance of $38.3 million, projected to fund operations into the early second half of 2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OVID","symbol_name":"Ovid Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL8nYnKH:1","article_id":"2559896147","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559896147","pubTimestamp":1755202116,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OVID":"Ovid Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Ovid Therapeutics Inc.推出针对神经过度兴奋状况的创新神经治疗产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OVID":0.9},"content_text":"Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions\n    \n\n        Ovid Therapeutics Inc. recently released a corporate presentation highlighting its focus on developing medicines for conditions caused by neural hyperexcitability. The company is advancing a pipeline of highly specific small molecules with differentiated mechanisms of action. Key programs include the GABA-aminotransferase inhibitor OV329 for drug-resistant adult epilepsies and developmental epileptic encephalopathies, with Phase 1 topline results expected in Q3 2025 and Phase 2a initiation in Q1 2026. The KCC2 direct activator portfolio features OV350 IV, currently in Phase 1, and OV4071 oral, aimed at psychosis associated with Parkinson's disease and Lewy body dementia, with upcoming Phase 1 trials. Ovid holds a cash balance of $38.3 million, projected to fund operations into the early second half of 2026. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}